C3 Glomerulonephritis
📧 Sign up to get email alerts when something new happens for C3 Glomerulonephritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies [Phase 2]
Phase II trial of APL-2 in glomerulopathies completed; results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-08-11Clinical Trial Update: A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 [Phase 2]
Phase 2 proof-of-concept trial for a 12-month treatment in C3 glomerulopathy-related conditions (C3 Glomerulonephritis/IC-MPGN) with ACH-014…
-
CLINICAL_TRIALS trial_result · 2021-11-04Clinical Trial Update: A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) [Phase 2]
Phase 2 proof-of-concept trial of danicopan for six months in participants with C3 glomerulopathy has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN [Phase 2]
Phase 2 trial assessing danicopan effects on C3 levels in participants with C3 glomerulopathy or IC-MPGN; the study is completed with result…
-
CLINICAL_TRIALS trial_result · 2014-03-07Clinical Trial Update: Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease [Phase 1]
A Phase 1 trial of CDX-1135 in pediatric and adult patients with Dense Deposit Disease and related glomerulonephritides was terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.